Niagen Bioscience, Inc. (NAGE)
NAGE moved a median of -0.32% 30 minutes after news, and -0.77% by the close. How NAGE actually reacts to news — the realized, point-in-time move the market made, measured across 105 labeled events over the last three years with zero look-ahead.
NAGE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.10% | 47% | 104 |
| 30-min | -0.32% | 39% | 105 |
| 60-min | -0.77% | 39% | 105 |
| to close | -0.77% | 38% | 103 |
| Middle 50% of NAGE reactions | -1.76% to +0.67% |
|---|---|
| Median reaction (30-min) | -0.32% |
| Measured reactions | 105 |
Half of all Niagen Bioscience, Inc. news events land between -1.76% and +0.67% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NAGE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NAGE's baseline. Nothing else.
Recent NAGE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026 | Press release | Business Wire | +0.79% | +1.57% | |
| Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN) | Press release | Business Wire | -0.74% | -1.48% | |
| Niagen Bioscience to Present at LD Micro 20th Annual Main Event | Press release | Business Wire | +0.38% | +0.75% | |
| Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater | Press release | Business Wire | -0.52% | -7.90% | |
| Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial | Press release | Business Wire | -0.67% | -1.68% | |
| Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes | Press release | Business Wire | +0.17% | +1.67% | |
| Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth | Press release | Business Wire | +0.84% | +0.00% | |
| Niagen Bioscience to Present at Canaccord Genuity’s Well Summit | Press release | Business Wire | -0.17% | +0.17% | |
| Niagen Bioscience to Present at Longevity Investors Conference | Press release | Business Wire | +1.60% | +1.28% | |
| Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit | Press release | Business Wire | -0.46% | +0.92% | |
| Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club | Press release | Business Wire | -1.42% | -0.63% | |
| Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference | Press release | Business Wire | -0.92% | -1.29% | |
| Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence | Press release | Business Wire | +0.68% | +3.40% | |
| Form 10-Q Niagen Bioscience, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.65% | -4.52% | |
| Form 8-K Niagen Bioscience, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | -4.52% | |
| Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +0.65% | -4.52% | |
| Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 | Press release | Business Wire | +1.72% | +1.15% | |
| Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging | Press release | Business Wire | +2.16% | +1.54% | |
| Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference | Press release | Business Wire | +0.62% | -0.61% | |
| Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 | Press release | Business Wire | +2.10% | +4.80% | |
| Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research | Press release | Business Wire | +0.58% | -1.45% | |
| Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) | Press release | Business Wire | -1.55% | -0.57% | |
| Form EFFECT Niagen Bioscience, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.15% | -2.59% | |
| Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026 | Press release | Business Wire | +1.93% | +3.56% | |
| Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases | Press release | Business Wire | +0.88% | -1.75% | |
| Form 8-K Niagen Bioscience, Inc. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.74% | |
| Form S-3 Niagen Bioscience, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.44% | -3.23% | |
| Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference | Press release | Business Wire | -0.43% | -1.71% | |
| Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science | Press release | Business Wire | -1.39% | -1.94% | |
| Niagen Bioscience Announces Participation in Upcoming Investor Conferences | Press release | Business Wire | -0.35% | -1.42% | |
| Form 10-Q Niagen Bioscience, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.99% | -3.68% | |
| Form 8-K Niagen Bioscience, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -2.99% | -3.68% | |
| Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results | Press release | Business Wire | -2.99% | -3.68% | |
| Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering | Press release | Business Wire | +3.01% | +0.82% | |
| Form ARS Niagen Bioscience, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.63% | -0.42% | |
| Form DEF 14A Niagen Bioscience, Inc. For: Jun 24 | SEC filing · Form DEF | SEC EDGAR | +0.63% | -0.42% | |
| Form DEFA14A Niagen Bioscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.63% | -0.42% | |
| Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™ | Press release | Business Wire | -0.10% | -2.62% | |
| Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | Press release | Business Wire | -0.21% | +4.37% | |
| Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen® | Press release | Business Wire | -0.66% | -1.10% | |
| Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas | Press release | Business Wire | -0.46% | +1.15% | |
| Form 8-K Niagen Bioscience, Inc. For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +3.30% | +0.85% | |
| Niagen Bioscience Increases Share Repurchase Program to $20 Million | Press release | Business Wire | +3.30% | +0.85% | |
| Niagen Bioscience to Present at the 38th Annual ROTH Conference | Press release | Business Wire | -0.42% | -3.81% | |
| Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies | Press release | Business Wire | +0.63% | +0.21% | |
| Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen® | Press release | Business Wire | +2.93% | +1.95% | |
| Form 10-K Niagen Bioscience, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.97% | -10.37% | |
| Form 8-K Niagen Bioscience, Inc. For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | -5.97% | -10.37% | |
| Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 | Press release | Business Wire | -5.97% | -10.37% | |
| Form 8-K Niagen Bioscience, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | -3.54% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NAGE section they belong to.
Where else NAGE is measured.
NAGE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Niagen Bioscience, Inc.'s median reaction calculated?
Every labeled NAGE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 105 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of NAGE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NAGE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.